108 related articles for article (PubMed ID: 28839735)
1. Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach.
Tait JM; Stephens BP; McIntyre PG; Evans M; Dillon JF
Frontline Gastroenterol; 2013 Oct; 4(4):255-262. PubMed ID: 28839735
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
4. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.
Radley A; Melville K; Tait J; Stephens B; Evans JMM; Dillon JF
Frontline Gastroenterol; 2017 Jul; 8(3):221-228. PubMed ID: 28839912
[TBL] [Abstract][Full Text] [Related]
5. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
6. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
[TBL] [Abstract][Full Text] [Related]
7. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Mbwambo J; Shimakawa Y; Poiteau L; Chevaliez S; Pawlotsky JM; Rwegasha J; Bhagani S; Taylor-Robinson SD; Makani J; Thursz MR; Lemoine M
J Int AIDS Soc; 2017 Sep; 20(1):21856. PubMed ID: 28953324
[TBL] [Abstract][Full Text] [Related]
9. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
Morey S; Hamoodi A; Jones D; Young T; Thompson C; Dhuny J; Buchanan E; Miller C; Hewett M; Valappil M; Hunter E; McPherson S
J Viral Hepat; 2019 Jan; 26(1):101-108. PubMed ID: 30315691
[TBL] [Abstract][Full Text] [Related]
10. Opportunistic assessment and treatment of people with hepatitis C virus infection admitted to hospital for other reasons: A prospective cohort study.
Chiong F; Post J
Int J Drug Policy; 2019 Mar; 65():50-55. PubMed ID: 30611857
[TBL] [Abstract][Full Text] [Related]
11. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
[TBL] [Abstract][Full Text] [Related]
12. Improving Screening Methods for Hepatitis C Among People Who Inject Drugs: Findings from the HepTLC Initiative, 2012-2014.
Blackburn NA; Patel RC; Zibbell JE
Public Health Rep; 2016; 131 Suppl 2(Suppl 2):91-7. PubMed ID: 27168667
[TBL] [Abstract][Full Text] [Related]
13. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
[TBL] [Abstract][Full Text] [Related]
14. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
[TBL] [Abstract][Full Text] [Related]
15. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.
Cypel M; Feld JJ; Galasso M; Pinto Ribeiro RV; Marks N; Kuczynski M; Kumar D; Bahinskaya I; Bagnato VS; Kurachi C; Slutsky AS; Yeung JC; Donahoe L; de Perrot M; Yasufuku K; Pierre A; Binnie M; Chaparro C; Martinu T; Chen M; Tikkanen J; Chow CW; Sidhu A; Waddell TK; Keshavjee S; Singer LG; Humar A
Lancet Respir Med; 2020 Feb; 8(2):192-201. PubMed ID: 31606437
[TBL] [Abstract][Full Text] [Related]
16. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
18. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a general practice based hepatitis C virus screening intervention.
Anderson EM; Mandeville RP; Hutchinson SJ; Cameron SO; Mills PR; Fox R; Ahmed S; Taylor A; Spence E; Goldberg DJ
Scott Med J; 2009 Aug; 54(3):3-7. PubMed ID: 19728405
[TBL] [Abstract][Full Text] [Related]
20. Routine screening for hepatitis C viral infection in patients undergoing elective cranial neurosurgery.
Nussbaum ES; Kallmes K; Lowary J; Nussbaum LA
J Neurosurg; 2018 Sep; 131(3):941-948. PubMed ID: 30215562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
